Prescriptions are too expensive because corrupt politicians are in the pockets of insurance companies and Big Pharma. The people received a victory this week, but we have a long way to go to achieve a just and equitable healthcare system.
Medicare Part D and the Urgency for Health Care Reform
Our Constitution prioritizes the general welfare of citizens, but when it comes to Medicare Part D, political interests have overshadowed the needs of the people. Addressing this issue and advocating for much-needed improvements in our healthcare system is crucial.
Medicare Part D, initiated in 2006 through Democratic efforts, could not negotiate drug prices. Democrats have recently succeeded in enabling negotiations to take place. It remains concerning that drug prices in the United States are significantly higher (200-300%) than in comparable countries.
Some have challenged these negotiations, claiming constitutional violations. However, it is essential to consider the bigger picture of prioritizing citizens' access to affordable medications and overall well-being.
Prioritizing Big Pharma over citizens is unjust. When Democrats capped insulin costs at $35/month, Rep. Jack Bergman opposed it. Now, it's time to stand up to the greed of Big Pharma and break their hold on corrupt politicians. We must lead in the fight for Medicare for All.
We must remember the intentions of our founding fathers and work towards a more equitable and compassionate healthcare system. We need a "Doctor in the House" who comprehends our healthcare complexities and is committed to enacting meaningful reform.
We need a publicly financed, national, non-profit health insurance program that comprehensively covers all Americans' medical costs. Medicare for All is morally and fiscally responsible and will save taxpayers $450 billion annually.
We must acknowledge the shortcomings of our current healthcare system, particularly regarding Medicare Part D and the soaring prices of prescription drugs.
Let us prioritize the needs of citizens over the interests of pharmaceutical companies and strive for a future where quality healthcare is accessible to all through meaningful reform.